Feature article: Lyme borreliosis prevention: a vaccine is on the way
Technical solution for a complicated separation problem in the downstream process
What is Lyme borreliosis?
No vaccine has yet been developed against Lyme borreliosis, a disease transmitted by ticks infected with Borrelia bacteria, which has been spreading dramatically over the past few years. Valneva, a biotech company developing innovative vaccines for infectious diseases, is now working on a new Lyme borreliosis vaccine. ZETA contributed to the production of the valuable active ingredient by providing the perfect technical solution to a complicated separation problem that occurred during the downstream process and thereby plays an important role in bringing an urgently needed vaccine to the market.
How many people get infected?
Lyme disease is the most common vector-borne disease in the northern hemisphere. (Diseases caused by mosquitoes, ticks and fleas that spread pathogens are termed “vector-borne”.) According to the U.S. Center for Disease Control and Prevention (CDC), about 300,000 Americans and 200,000 Europeans contract Lyme disease each year.
The global footprint of the disease is expanding
The global footprint of the disease is expanding; probably due to climate change and warmer winters, ticks are found in places where they have never been observed before. A few decades ago, Lyme was confined to a few small areas, but is now spreading far beyond its usual territory. Particularly in Europe, the number of confirmed cases has been rising steadily over the past 30 years.
The time is ripe for a Lyme disease vaccine
Good news: Valneva is working on a new Lyme disease vaccine.
ZETA Blog
Whitepaper Download
Our expert is looking forward
to hearing from you!
Related Posts
ZETA Blog